Survey Results and Recommendations from Japanese Stakeholders for Good Clinical Practice Renovation

• Published in: Therapeutic innovation & regulatory science Vol. 56; no. 2; pp. 220 - 229
• Main Authors: Nakamura, Kenichi, Ozawa, Hitoshi, Shibata, Taro, Ushirozawa, Nobuko, Hata, Tomomi, Okita, Natsuko, Fuse, Nozomu, Sato, Norihiro, Ikeda, Koji, Hanaoka, Hideki, Maruyama, Tatsuya, Wada, Michihiko, Shimizu, Shinobu, Kasai, Hiroi, Yamamoto, Yoichi, Sakurai, Jun, Todaka, Koji, Tashiro, Shimon, Yamamoto, Haruko
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.03.2022; Springer Nature B.V
• Subjects: Clinical medicine; Clinical trials; Drug Safety and Pharmacovigilance; Ethics; Informed consent; Liquidity; Medicine; Modernization; Monitoring; Original Research; Patients; Pharmacotherapy; Pharmacy; Polls & surveys; Quality assurance; Japan; International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; Good Clinical Practice; Clinical trial regulation; Remote monitoring; Real-world data
• ISSN: 2168-4790; 2168-4804
• DOI: 10.1007/s43441-021-00350-4

Background The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is undertaking a major revision of ICH E6 Good Clinical Practice (GCP) decided to involve external stakeholders in ICH-GCP renovation. Activities such as surveys and public conferences have taken place in the United States, European Union, and Japan. For stakeholder engagement in Japan, a designated research group conducted a survey of academic stakeholders. Methods A total of 105 academic stakeholders from 18 institutions responded to the survey. The research group developed recommendations reflecting the survey results and the opinions from patients and the public. Results The survey showed the top four principles needing renovation were (i) informed consent (Chapter 2.9, 12.4% of respondents believed it needed renovation), (ii) systems for quality assurance (Chapter 2.13, 9.5%), (iii) information on an investigational product (Chapter 2.4, 5.7%), and (iv) procedures on clinical trial information (Chapter 2.10, 5.7%). The top three sections identified as needing renovation were: (i) informed consent (Chapter 4.8, 27.6%), (ii) monitoring (Chapter 5.18, 22.9%), and (iii) composition, functions, and operations of the ethics committee (Chapter 3.2, 14.3%). Recommendations included clarification of ICH-GCP’s scope, proportionality in various aspects of clinical trials, diversity and liquidity of ethics committee members, modernization of informed consent procedures, variations in monitoring, and regulatory grade when using real-world data. Conclusion The recommendations from Japanese investigators and patients have been submitted to the ICH E6 Expert Working Group, which will strengthen the robustness of the GCP renovation.